Bolge Susan C, Flores Natalia M, Huang Shu, Cai Jennifer
anssen Scientific Affairs, LLC, Titusville, NJ.
Kantar Health, Foster City, CA.
Int J Gen Med. 2017 Jun 23;10:177-187. doi: 10.2147/IJGM.S138583. eCollection 2017.
This study describes how health care providers approach canagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) in the real world.
An Internet-based questionnaire was completed by 101 endocrinologists, 101 primary care physicians, and 100 nurse practitioners/physician assistants (NP/PAs). Health care providers were required to have experience prescribing or managing patients using canagliflozin to be included in the study. Health care providers compared canagliflozin with other T2DM medication classes on clinical characteristics, costs, and patient satisfaction. Confidence in canagliflozin was also measured. Health care providers reported their canagliflozin prescribing experience and good candidate characteristics for treatment. Finally, providers reported on patient outcomes among those receiving canagliflozin. All variables were compared across provider type.
Health care providers reported higher favorability for canagliflozin for blood pressure and body weight compared with dipeptidyl peptidase-4 (DPP-4) inhibitors and higher favorability for effect on blood pressure, body weight, treatment satisfaction, and glycosylated hemoglobin (HbA1c) compared with sulfonylureas (SUs), with differences observed for effect on blood pressure. Health care providers reported being very/extremely confident (55%-74%) with canagliflozin as a second-to fourth-line treatment. The top 3 characteristics reported by the providers, in terms of describing a good candidate for canagliflozin, include those concerned about their weight, insurance coverage/affordability, and avoiding injectable treatments. Finally, providers reported often/always observing patients' lowering or controlling HbA1c (82%-88%) and improvement in overall quality of life (QoL; 50%-53%) with canagliflozin treatment. No differences were observed across provider type for confidence, good candidate characteristics, or patient outcomes.
Health care providers reported favorable experiences with canagliflozin and witnessed improvements in patients' clinical outcomes and QoL.
本研究描述了医疗服务提供者在现实世界中如何使用卡格列净治疗2型糖尿病（T2DM）患者。
101名内分泌科医生、101名初级保健医生和100名执业护士/医师助理（NP/PA）完成了一份基于互联网的调查问卷。医疗服务提供者必须有使用卡格列净为患者开处方或进行管理的经验才能纳入研究。医疗服务提供者将卡格列净与其他T2DM药物类别在临床特征、成本和患者满意度方面进行了比较。还测量了对卡格列净的信心。医疗服务提供者报告了他们使用卡格列净的处方经验以及适合治疗的良好候选特征。最后，提供者报告了接受卡格列净治疗的患者的治疗结果。对所有变量按提供者类型进行了比较。
与二肽基肽酶-4（DPP-4）抑制剂相比，医疗服务提供者报告卡格列净对血压和体重的好感度更高；与磺脲类药物（SUs）相比，卡格列净对血压、体重、治疗满意度和糖化血红蛋白（HbA1c）的影响好感度更高，在血压影响方面观察到差异。医疗服务提供者报告对卡格列净作为二线至四线治疗非常/极其有信心（55%-74%）。就描述卡格列净的良好候选者而言，提供者报告的前3个特征包括那些担心体重、保险覆盖范围/可承受性以及避免注射治疗的患者。最后，提供者报告在卡格列净治疗中经常/总是观察到患者的HbA1c降低或得到控制（82%-88%）以及总体生活质量（QoL）改善（50%-53%）。在信心、良好候选特征或患者结果方面，未观察到不同提供者类型之间存在差异。
医疗服务提供者报告了使用卡格列净的良好经验，并见证了患者临床结果和QoL的改善。
